Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

BMJ, 01 Jan 1994, 308(6921):81-106
PMID: 8298418 PMCID: PMC2539220

Free full text in Europe PMC

A comment on this article appears in "" ACP J Club. 1994 Jul-Aug;121 Suppl 1:4-6. This article has been corrected. See BMJ 1994 Jun 11;308(6943):1540. A comment on this article appears in "" BMJ. 1994 Jan 8;308(6921):71-2. Show all (5)

Abstract 

Objective

To determine the effects of "prolonged" antiplatelet therapy (that is, given for one month or more) on "vascular events" (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) in various categories of patients.

Design

Overviews of 145 randomised trials of "prolonged" antiplatelet therapy versus control and 29 randomised comparisons between such antiplatelet regimens.

Setting

Randomised trials that could have been available by March 1990.

Subjects

Trials of antiplatelet therapy versus control included about 70,000 "high risk" patients (that is, with some vascular disease or other condition implying an increased risk of occlusive vascular disease) and 30,000 "low risk" subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10,000 high risk patients.

Results

In each of four main high risk categories of patients antiplatelet therapy was definitely protective. The percentages of patients suffering a vascular event among those allocated antiplatelet therapy versus appropriately adjusted control percentages (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 20,000 patients with acute myocardial infarction, 10% antiplatelet therapy v 14% control (one month benefit about 40 vascular events avoided per 1000 patients treated (2P < 0.00001)); (b) among about 20,000 patients with a past history of myocardial infarction, 13% antiplatelet therapy v 17% control (two year benefit about 40/1000 (2P < 0.00001)); (c) among about 10,000 patients with a past history of stroke or transient ischaemic attack, 18% antiplatelet therapy v 22% control (three year benefit about 40/1000 (2P < 0.00001)); (d) among about 20,000 patients with some other relevant medical history (unstable angina, stable angina, vascular surgery, angioplasty, atrial fibrillation, valvular disease, peripheral vascular disease, etc), 9% v 14% in 4000 patients with unstable angina (six month benefit about 50/1000 (2P < 0.00001)) and 6% v 8% in 16,000 other high risk patients (one year benefit about 20/1000 (2P < 0.00001)). Reductions in vascular events were about one quarter in each of these four main categories and were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and nondiabetic patients. Taking all high risk patients together showed reductions of about one third in non-fatal myocardial infarction, about one third in non-fatal stroke, and about one third in vascular death (each 2P < 0.00001). There was no evidence that non-vascular deaths were increased, so in each of the four main high risk categories overall mortality was significantly reduced. The most widely tested antiplatelet regimen was "medium dose" (75-325 mg/day) aspirin. Doses throughout this range seemed similarly effective (although in an acute emergency it might be prudent to use an initial dose of 160-325 mg rather than about 75 mg). There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events. The optimal duration of treatment for patients with a past history of myocardial infarction, stroke, or transient ischaemic attack could not be determined directly because most trials lasted only one, two, or three years (average about two years). Nevertheless, there was significant (2P < 0.0001) further benefit between the end of year 1 and the end of year 3, suggesting that longer treatment might well be more effective. Among low risk recipients of "primary prevention" a significant reduction of one third in non-fatal myocardial infarction was, however, accompanied by a non-significant increase in stroke. Furthermore, the absolute reduction in vascular events was much smaller than for high risk patients despite a much longer treatment period (4.4% antiplatelet therapy v 4.8% control; five year

Free full text 

Logo of bmjThe BMJ
BMJ. 1994 Jan 8; 308(6921): 81–106.
PMCID: PMC2539220
PMID: 8298418

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Copyright and License information Disclaimer

Abstract

OBJECTIVE--To determine the effects of "prolonged" antiplatelet therapy (that is, given for one month or more) on "vascular events" (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) in various categories of patients. DESIGN--Overviews of 145 randomised trials of "prolonged" antiplatelet therapy versus control and 29 randomised comparisons between such antiplatelet regimens. SETTING--Randomised trials that could have been available by March 1990. SUBJECTS--Trials of antiplatelet therapy versus control included about 70,000 "high risk" patients (that is, with some vascular disease or other condition implying an increased risk of occlusive vascular disease) and 30,000 "low risk" subjects from the general population. Direct comparisons of different antiplatelet regimens involved about 10,000 high risk patients. RESULTS--In each of four main high risk categories of patients antiplatelet therapy was definitely protective. The percentages of patients suffering a vascular event among those allocated antiplatelet therapy versus appropriately adjusted control percentages (and mean scheduled treatment durations and net absolute benefits) were: (a) among about 20,000 patients with acute myocardial infarction, 10% antiplatelet therapy v 14% control (one month benefit about 40 vascular events avoided per 1000 patients treated (2P < 0.00001)); (b) among about 20,000 patients with a past history of myocardial infarction, 13% antiplatelet therapy v 17% control (two year benefit about 40/1000 (2P < 0.00001)); (c) among about 10,000 patients with a past history of stroke or transient ischaemic attack, 18% antiplatelet therapy v 22% control (three year benefit about 40/1000 (2P < 0.00001)); (d) among about 20,000 patients with some other relevant medical history (unstable angina, stable angina, vascular surgery, angioplasty, atrial fibrillation, valvular disease, peripheral vascular disease, etc), 9% v 14% in 4000 patients with unstable angina (six month benefit about 50/1000 (2P < 0.00001)) and 6% v 8% in 16,000 other high risk patients (one year benefit about 20/1000 (2P < 0.00001)). Reductions in vascular events were about one quarter in each of these four main categories and were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and nondiabetic patients. Taking all high risk patients together showed reductions of about one third in non-fatal myocardial infarction, about one third in non-fatal stroke, and about one third in vascular death (each 2P < 0.00001). There was no evidence that non-vascular deaths were increased, so in each of the four main high risk categories overall mortality was significantly reduced. The most widely tested antiplatelet regimen was "medium dose" (75-325 mg/day) aspirin. Doses throughout this range seemed similarly effective (although in an acute emergency it might be prudent to use an initial dose of 160-325 mg rather than about 75 mg). There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events. The optimal duration of treatment for patients with a past history of myocardial infarction, stroke, or transient ischaemic attack could not be determined directly because most trials lasted only one, two, or three years (average about two years). Nevertheless, there was significant (2P < 0.0001) further benefit between the end of year 1 and the end of year 3, suggesting that longer treatment might well be more effective. Among low risk recipients of "primary prevention" a significant reduction of one third in non-fatal myocardial infarction was, however, accompanied by a non-significant increase in stroke. Furthermore, the absolute reduction in vascular events was much smaller than for high risk patients despite a much longer treatment period (4.4% antiplatelet therapy v 4.8% control; five year

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (5.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 81
81
icon of scanned page 82
82
icon of scanned page 83
83
icon of scanned page 84
84
icon of scanned page 85
85
icon of scanned page 86
86
icon of scanned page 87
87
icon of scanned page 88
88
icon of scanned page 89
89
icon of scanned page 90
90
icon of scanned page 91
91
icon of scanned page 92
92
icon of scanned page 93
93
icon of scanned page 94
94
icon of scanned page 95
95
icon of scanned page 96
96
icon of scanned page 97
97
icon of scanned page 98
98
icon of scanned page 99
99
icon of scanned page 100
100
icon of scanned page 101
101
icon of scanned page 102
102
icon of scanned page 103
103
icon of scanned page 104
104
icon of scanned page 105
105
icon of scanned page 106
106
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989 Oct;80(4):749–756. [Abstract] [Google Scholar]
  • Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation. 1993 Feb;87(2):659–675. [Abstract] [Google Scholar]
  • Peto R. Why do we need systematic overviews of randomized trials? Stat Med. 1987 Apr-May;6(3):233–244. [Abstract] [Google Scholar]
  • Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987 Apr-May;6(3):245–254. [Abstract] [Google Scholar]
  • Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986 Oct;4(10):1529–1541. [Abstract] [Google Scholar]
  • Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990 Mar 9;263(10):1385–1389. [Abstract] [Google Scholar]
  • Mendelow AD, Stockdill G, Steers AJ, Hayes J, Gillingham FJ. Double-blind trial of aspirin in patient receiving tranexamic acid for subarachnoid hemorrhage. Acta Neurochir (Wien) 1982;62(3-4):195–202. [Abstract] [Google Scholar]
  • Shaw MD, Foy PM, Conway M, Pickard JD, Maloney P, Spillane JA, Chadwick DW. Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage. J Neurosurg. 1985 Nov;63(5):699–703. [Abstract] [Google Scholar]
  • Ono H, Mizukami M, Kitamura K, Kikuchi H. Ticlopidine: quo vadis? Subarachnoid hemorrhage. Agents Actions Suppl. 1984;15:259–272. [Abstract] [Google Scholar]
  • Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974 Mar 9;1(5905):436–440. [Europe PMC free article] [Abstract] [Google Scholar]
  • Elwood P. Trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J (Clin Res Ed) 1981 Feb 7;282(6262):481–481. [Europe PMC free article] [Abstract] [Google Scholar]
  • Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol. 1986 Feb;7(2):251–269. [Abstract] [Google Scholar]
  • Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis. 1980;9(6):325–344. [Abstract] [Google Scholar]
  • Temple R, Pledger GW. The FDA's critique of the anturane reinfarction trial. N Engl J Med. 1980 Dec 18;303(25):1488–1492. [Abstract] [Google Scholar]
  • Vogel G, Fischer C, Huyke R. Reinfarktprophylaxe mit Azetylsalizylsäure. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):797–803. [Abstract] [Google Scholar]
  • Gent AE, Brook CG, Foley TH, Miller TN. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. Br Med J. 1968 Nov 9;4(5627):366–368. [Europe PMC free article] [Abstract] [Google Scholar]
  • Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J. 1993 Jul;14(7):951–957. [Abstract] [Google Scholar]
  • Rasmanis G, Vesterqvist O, Gréen K, Edhag O, Henriksson P. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet. 1988 Jul 30;2(8605):245–247. [Abstract] [Google Scholar]
  • Knudsen JB, Kjøller E, Skagen K, Gormsen J. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost. 1985 Jun 24;53(3):332–336. [Abstract] [Google Scholar]
  • Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977 May-Jun;8(3):301–314. [Abstract] [Google Scholar]
  • Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke. 1978 Jul-Aug;9(4):309–319. [Abstract] [Google Scholar]
  • Lemak NA, Fields WS, Gary HE., Jr Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology. 1986 May;36(5):705–710. [Abstract] [Google Scholar]
  • Reuther R, Dorndorf W, Loew D. Behandlung transitorisch-ischämischer Attacken mit Azetylsalizylsäure Ergebnisse einer Doppelblindstudie. MMW Munch Med Wochenschr. 1980 May 23;122(21):795–798. [Abstract] [Google Scholar]
  • Gent M, Barnett HJ, Sackett DL, Taylor DW. A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues. Circulation. 1980 Dec;62(6 Pt 2):V97–105. [Abstract] [Google Scholar]
  • Whisnant JP. The Canadian trial of aspirin and sulfinpyrazone in threatened stroke. Am Heart J. 1980 Jan;99(1):129–130. [Abstract] [Google Scholar]
  • Guiraud-Chaumeil B, Rascol A, David J, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires. Résultats d'un essai thérapeutique contrôlé de 3 ans. Rev Neurol (Paris) 1982;138(5):367–385. [Abstract] [Google Scholar]
  • Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D, Touboul PJ. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 1983 Jan-Feb;14(1):5–14. [Abstract] [Google Scholar]
  • Bousser MG, Eschwège E, Haguenau M, Lefauconnier JM, Thibult N, Touboul D, Touboul PJ. Essai coopératif contrôlé de prévention secondaire des accidents ischémiques cérébraux liés à l'athérosclérose par l'aspirine et le dipyridamole. Presse Med. 1983 Dec 29;12(48):3049–3057. [Abstract] [Google Scholar]
  • Sorensen PS, Pedersen H, Marquardsen J, Petersson H, Heltberg A, Simonsen N, Munck O, Andersen LA. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke. 1983 Jan-Feb;14(1):15–22. [Abstract] [Google Scholar]
  • High-dose acetylsalicylic acid after cerebral infarction. A Swedish Cooperative Study. Stroke. 1987 Mar-Apr;18(2):325–334. [Abstract] [Google Scholar]
  • Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J. 1969 Mar 8;1(5644):614–615. [Europe PMC free article] [Abstract] [Google Scholar]
  • Acheson J, Danta G, Hutchinson EC. Platelet adhesiveness in patients with cerebral vascular disease. Atherosclerosis. 1972 Jan-Feb;15(1):123–127. [Abstract] [Google Scholar]
  • Robertson JT, Dugdale M, Salky N, Robinson H. Proceedings: The effect of a platelet inhibiting drug (sulfinpyrazone) in the therapy of patients with transient ischemic attacks (Tia's) and minor strokes. Thromb Diath Haemorrh. 1975 Nov 15;34(2):598–598. [Abstract] [Google Scholar]
  • Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke. 1988 Oct;19(10):1203–1210. [Abstract] [Google Scholar]
  • Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989 Jun 3;1(8649):1215–1220. [Abstract] [Google Scholar]
  • Gent M, Blakely JA, Hachinski V, Roberts RS, Barnett HJ, Bayer NH, Carruthers SG, Collins SM, Gawel MG, Giroux-Klimek M, et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke. 1985 May-Jun;16(3):416–424. [Abstract] [Google Scholar]
  • Roden S, Low-Beer T, Carmalt M, Cockel R, Green I. Transient cerebral ischaemic attacks--management and prognosis. Postgrad Med J. 1981 May;57(667):275–278. [Europe PMC free article] [Abstract] [Google Scholar]
  • Lewis HD, Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. [Abstract] [Google Scholar]
  • Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985 Nov 28;313(22):1369–1375. [Abstract] [Google Scholar]
  • Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol. 1991 Dec;18(7):1587–1593. [Abstract] [Google Scholar]
  • Nyman I, Larsson H, Wallentin L. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Lancet. 1992 Aug 29;340(8818):497–501. [Abstract] [Google Scholar]
  • Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990 Jul;82(1):17–26. [Abstract] [Google Scholar]
  • Prandoni P, Milani L, Barbiero M, Cardaioli P, Sanson A, Barbaresi F, Zonzin P, Visani L. Trattamento dell'angina instabile con dipiridamolo associato a basse dosi di aspirina. Studio multicentrico pilota in doppio-cieco controllato. Minerva Cardioangiol. 1991 Jul-Aug;39(7-8):267–273. [Abstract] [Google Scholar]
  • Roelandt JR, Sutherland GR. Oesophageal echocardiography. Br Heart J. 1988 Jul;60(1):1–3. [Europe PMC free article] [Abstract] [Google Scholar]
  • Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR, Jr, Vlietstra RE, Pluth JR, et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982 Jul 8;307(2):73–78. [Abstract] [Google Scholar]
  • Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984 Jan 26;310(4):209–214. [Abstract] [Google Scholar]
  • Chesebro JH, Fuster V. Pathogenesis and prevention of aortocoronary bypass graft occlusion. Int J Clin Pharmacol Res. 1986;6(4):261–267. [Abstract] [Google Scholar]
  • Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg. 1984 May;37(5):371–378. [Abstract] [Google Scholar]
  • Limet R, David JL, Rigo P. Ticlopidine and coronary surgery. Agents Actions Suppl. 1984;15:188–198. [Abstract] [Google Scholar]
  • Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg. 1987 Nov;94(5):773–783. [Abstract] [Google Scholar]
  • Pantely GA, Goodnight SH, Jr, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, Rösch J. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med. 1979 Nov 1;301(18):962–966. [Abstract] [Google Scholar]
  • Brown BG, Cukingnan RA, DeRouen T, Goede LV, Wong M, Fee HJ, Roth JA, Carey JS. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation. 1985 Jul;72(1):138–146. [Abstract] [Google Scholar]
  • Greenough A, Wood S, Morley CJ, Davis JA. Pancuronium prevents pneumothoraces in ventilated premature babies who actively expire against positive pressure inflation. Lancet. 1984 Jan 7;1(8367):1–3. [Abstract] [Google Scholar]
  • Meister W, von Schacky C, Weber M, Lorenz R, Kotzur J, Reichart B, Theisen K, Weber PC. Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a placebo-controlled trial. Br J Clin Pharmacol. 1984 Jun;17(6):703–711. [Europe PMC free article] [Abstract] [Google Scholar]
  • Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation. 1988 Jun;77(6):1324–1332. [Abstract] [Google Scholar]
  • Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation. 1989 Jul;80(1):1–9. [Abstract] [Google Scholar]
  • Sanz G, Pajarón A, Alegría E, Coello I, Cardona M, Fournier JA, Gómez-Recio M, Ruano J, Hidalgo R, Medina A, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC) Circulation. 1990 Sep;82(3):765–773. [Abstract] [Google Scholar]
  • Pfisterer M, Burkart F, Jockers G, Meyer B, Regenass S, Burckhardt D, Schmitt HE, Müller-Brand J, Skarvan K, Stulz P. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet. 1989 Jul 1;2(8653):1–7. [Abstract] [Google Scholar]
  • Rajah SM, Salter MC, Donaldson DR, Subba Rao R, Boyle RM, Partridge JB, Watson DA. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg. 1985 Sep;90(3):373–377. [Abstract] [Google Scholar]
  • Pirk J, Vojácek J, Kovác J, Fabián J, Firt P. Improved patency of the aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg. 1986 Sep;42(3):312–314. [Abstract] [Google Scholar]
  • Thaulow E, Frøysaker T, Dale J, Vatne K. Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of aortocoronary venous bypass graft. Scand J Thorac Cardiovasc Surg. 1987;21(3):215–220. [Abstract] [Google Scholar]
  • Guiteras P, Altimiras J, Arís A, Augé JM, Bassons T, Bonal J, Caralps JM, Castellarnau C, Crexells C, Masotti M, et al. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 1989 Feb;10(2):159–167. [Abstract] [Google Scholar]
  • Higgins CB. Nuclear magnetic resonance (NMR) imaging in ischemic heart disease. J Am Coll Cardiol. 1990 Jan;15(1):150–151. [Abstract] [Google Scholar]
  • Phillips SJ, Kongtahworn C, Zeff RH, Beshany SE. Antiplatelet and anticoagulant therapy after coronary bypass. N Engl J Med. 1980 Apr 10;302(15):866–866. [Abstract] [Google Scholar]
  • Cade JF, Doyle DJ, Chesterman CN, Morgan FJ, Rennie GC. Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone. Circulation. 1982 Jul;66(1):29–32. [Abstract] [Google Scholar]
  • Schwartz L, Bourassa MG, Lespérance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988 Jun 30;318(26):1714–1719. [Abstract] [Google Scholar]
  • Sbar S, Schlant RC. Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA. 1967 Sep 11;201(11):865–867. [Abstract] [Google Scholar]
  • Berglund U, Lassvik C, Wallentin L. Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J. 1987 Jan;8(1):25–30. [Abstract] [Google Scholar]
  • Berglund U, von Schenck H, Wallentin L. Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost. 1985 Dec 17;54(4):808–812. [Abstract] [Google Scholar]
  • Wirecki M. Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis. 1967 Mar;20(3):139–145. [Abstract] [Google Scholar]
  • Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989 Jan 28;1(8631):175–179. [Abstract] [Google Scholar]
  • Steele P, Rainwater J. Favorable effect of sulfinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation. 1980 Sep;62(3):462–465. [Abstract] [Google Scholar]
  • Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med. 1971 Jun 24;284(25):1391–1394. [Abstract] [Google Scholar]
  • Loeliger EA. Dipyridamole as an antithrombotic drug. N Engl J Med. 1988 Oct 6;319(14):951–952. [Abstract] [Google Scholar]
  • Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1976 Jul;72(1):127–129. [Abstract] [Google Scholar]
  • Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J. 1977 Jul;94(1):101–111. [Abstract] [Google Scholar]
  • Starkman C, Estampes B, Vernant P, Acar J. Prévention des accidents thromboemboliques systémiques chez les patients porteurs de prothèses valvulaires artificielles. Essai prospectif de l'association antivitamines K-dipyridamol. Arch Mal Coeur Vaiss. 1982 Jan;75(1):85–88. [Abstract] [Google Scholar]
  • Ciavarella N, Antoncecchi S, D'Elia N. Dipiridamolo e warfarina in pazienti portatori di protesi valvolari cardiache artificiali: sperimentazione in doppio cieco. Cardiologia. 1985 Apr;30(4):301–307. [Abstract] [Google Scholar]
  • Colwell JA, Bingham SF, Abraira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr;9(2):140–148. [Abstract] [Google Scholar]
  • Colwell JA, Bingham SF, Abraira C, Anderson JW, Kwaan HC. V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Control Clin Trials. 1984 Jun;5(2):165–183. [Abstract] [Google Scholar]
  • Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet. 1985 Feb 23;1(8426):415–419. [Abstract] [Google Scholar]
  • Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgärde F, Persson G, Almgren B, Fagher B, Kjellström T, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990 May;227(5):301–308. [Abstract] [Google Scholar]
  • Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol. 1982 Jul;35(7):740–743. [Europe PMC free article] [Abstract] [Google Scholar]
  • Destors JM, Arcan JC. Evaluation des médicaments par voie orale de la claudication intermittente des membres inférieurs à la phase III des essais cliniques. Choix retenus dans l'étude ACT. Therapie. 1985 Nov-Dec;40(6):451–458. [Abstract] [Google Scholar]
  • Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988 Sep;39(9):802–811. [Abstract] [Google Scholar]
  • Stiegler H, Hess H, Mietaschk A, Trampisch HJ, Ingrisch H. Einfluss von Ticlopidin auf die periphere obliterierende Arteriopathie. Dtsch Med Wochenschr. 1984 Aug 17;109(33):1240–1243. [Abstract] [Google Scholar]
  • Schoop W. Spätergebnisse bei konservativer Therapie der arteriellen Verschlusskrankheit. Internist (Berl) 1984 Jul;25(7):429–433. [Abstract] [Google Scholar]
  • Jones NA, De Haas H, Zahavi J, Kakkar VV. A double-blind trial of suloctidil v. placebo in intermittent claudication. Br J Surg. 1982 Jan;69(1):38–40. [Abstract] [Google Scholar]
  • Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Angiology. 1982 Jun;33(6):357–367. [Abstract] [Google Scholar]
  • Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989 Jul;114(1):84–91. [Abstract] [Google Scholar]
  • Adriaensen H. Medical treatment of intermittent claudication: a comparative double-blind study of suloctidil, dihydroergotoxine and placebo. Curr Med Res Opin. 1976;4(6):395–401. [Abstract] [Google Scholar]
  • Holm J, Lindblad L, Scherstén T, Suurkula M. Intermittent claudication: Suloctidil v.s. placebo treatment. Vasa. 1984;13(2):175–178. [Abstract] [Google Scholar]
  • Signorini GP, Salmistraro G, Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology. 1988 Aug;39(8):742–746. [Abstract] [Google Scholar]
  • Verhaeghe R, Van Hoof A, Beyens G. Controlled trial of suloctidil in intermittent claudication. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):279–286. [Abstract] [Google Scholar]
  • Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery. 1982 Dec;92(6):1016–1026. [Abstract] [Google Scholar]
  • McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 1991 Jan;13(1):150–162. [Abstract] [Google Scholar]
  • Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, Skillman J, Couch NP, Whittemore AD, Mannick JA, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery. 1984 Sep;96(3):462–466. [Abstract] [Google Scholar]
  • Boehme K, Loew D, Artik N. Planung, Durchführung und biometrische Auswertung einer Langzeitstudie mit Acetylsalicylsäure. Med Welt. 1977 Jul 1;28(26):1163–1166. [Abstract] [Google Scholar]
  • Ehresmann U, Alemany J, Loew D. Prophylaxe von Rezidivverschlüssen nach Revaskularisations-eingriffen mit Acetylsalicylsäure. Ergebnisse einer doppeltblinden Langzeitstudie. Med Welt. 1977 Jul 1;28(26):1157–1162. [Abstract] [Google Scholar]
  • Comberg HU, Janssen EJ, Diehm C, Zimmermann R, Harenberg J, Walter E, Oster P, Allenberg J, Horsch AK, Mörl H. Sulfinpyrazon (Anturan) versus Placebo nach operativer Rekonstruktion der Oberschenkeletage bei arterieller Verschlusskrankheit. Vasa. 1983;12(2):172–178. [Abstract] [Google Scholar]
  • Castelli P, Basellini A, Agus GB, Ippolito E, Pogliani EM, Colombi M, Gianese F, Scatigna M. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg. 1986 Oct-Dec;71(4):252–255. [Abstract] [Google Scholar]
  • Goldman M, Hall C, Dykes J, Hawker RJ, McCollum CN. Does 111indium-platelet deposition predict patency in prosthetic arterial grafts? Br J Surg. 1983 Oct;70(10):635–638. [Abstract] [Google Scholar]
  • Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology. 1990 Apr;41(4):263–269. [Abstract] [Google Scholar]
  • Mahler F, Schneider E, Gallino A, Bollinger A. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA. Vasa. 1987;16(4):381–385. [Abstract] [Google Scholar]
  • Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. Arteriovenous-shunt thrombosis. Prevention by sulfinpyrazone. N Engl J Med. 1974 Feb 7;290(6):304–306. [Abstract] [Google Scholar]
  • Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M. The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Circulation. 1975 Sep;52(3):497–499. [Abstract] [Google Scholar]
  • Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med. 1979 Sep 13;301(11):577–579. [Abstract] [Google Scholar]
  • Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, Möhring K. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr. 1974 Apr 1;52(7):348–349. [Abstract] [Google Scholar]
  • Kobayashi K, Maeda K, Koshikawa S, Kawaguchi Y, Shimizu N, Naito C. Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study. Thromb Res. 1980 Oct 15;20(2):255–261. [Abstract] [Google Scholar]
  • Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs. 1985 Feb;9(1):61–63. [Abstract] [Google Scholar]
  • Mirouze J. Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study). Agents Actions Suppl. 1984;15:230–258. [Abstract] [Google Scholar]
  • Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohmé G. A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study. Clin Nephrol. 1984 Mar;21(3):184–187. [Abstract] [Google Scholar]
  • Barnett AH, Wakelin K, Leatherdale BA, Britton JR, Polak A, Bennett J, Toop M, Rowe D, Dallinger K. Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet. 1984 Jun 16;1(8390):1322–1325. [Abstract] [Google Scholar]
  • Schreiber U, Hartung B. Postoperative Thromboembolieprophylaxe bei Patienten mit allgemeinchirurgischen Operationen. Zentralbl Chir. 1979;104(18):1214–1220. [Abstract] [Google Scholar]
  • Hartung B, Schreiber U, Rödiger H. Testung des Thrombozytenaggregationshemmers MICRISTIN auf seine Wirksamkeit als Thromboembolieprophylaktikum in der postoperativen Phase nach chirurgischen Eingriffen. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):810–827. [Abstract] [Google Scholar]
  • Green D, Rossi EC, Yao JS, Flinn WR, Spies SM. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia. 1982 Aug;20(4):227–234. [Abstract] [Google Scholar]
  • Steele P, Ellis J, Jr, Genton E. Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med. 1978 Mar;64(3):441–445. [Abstract] [Google Scholar]
  • Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet. 1980 Dec 20;2(8208-8209):1328–1329. [Abstract] [Google Scholar]
  • Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 Jun;37(6):549–555. [Abstract] [Google Scholar]
  • Houtsmuller AJ, Vermeulen JA, Klompe M, Zahn KJ, Henkes HE, Baarsma GS, Tijssen J. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl. 1984;15:219–229. [Abstract] [Google Scholar]
  • Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. [Europe PMC free article] [Abstract] [Google Scholar]
  • Hass WK, Kamm B. The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics. Agents Actions Suppl. 1984;15:273–278. [Abstract] [Google Scholar]
  • Hass WK, Easton JD, Adams HP, Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989 Aug 24;321(8):501–507. [Abstract] [Google Scholar]
  • Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G. A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke. 1982 Mar-Apr;13(2):175–179. [Abstract] [Google Scholar]
  • Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation. 1990 Aug;82(2):507–513. [Abstract] [Google Scholar]
  • Riess H, Höfling B, von Arnim T, Hiller E. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. Thromb Res. 1986 Apr 15;42(2):235–245. [Abstract] [Google Scholar]
  • Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharmacol Res. 1986;6(1):59–60. [Abstract] [Google Scholar]
  • Bollinger A, Brunner U. Antiplatelet drugs improve the patency rates after femoro-popliteal endarterectomy. Vasa. 1985;14(3):272–279. [Abstract] [Google Scholar]
  • Elwood PC, Williams WO. A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Coll Gen Pract. 1979 Jul;29(204):413–416. [Europe PMC free article] [Abstract] [Google Scholar]
  • Johannessen KA, Stratton JR, Taulow E, Osterud B, von der Lippe G. Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction. Am J Cardiol. 1989 Jan 1;63(1):101–102. [Abstract] [Google Scholar]
  • Wilcox RG, Richardson D, Hampton JR, Mitchell JR, Banks DC. Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function. Br Med J. 1980 Aug 23;281(6239):531–534. [Europe PMC free article] [Abstract] [Google Scholar]
  • Ciuffetti G, Aisa G, Mercuri M, Lombardini R, Paltriccia R, Neri C, Senin U. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology. 1990 Jul;41(7):505–511. [Abstract] [Google Scholar]
  • Findlay JM, Lougheed WM, Gentili F, Walker PM, Glynn MF, Houle S. Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans. J Neurosurg. 1985 Nov;63(5):693–698. [Abstract] [Google Scholar]
  • Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, deGuise P, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988 Oct 27;319(17):1105–1111. [Abstract] [Google Scholar]
  • Baur HR, VanTassel RA, Pierach CA, Gobel FL. Effects of sulfinpyrazone on early graft closure after myocardial revascularization. Am J Cardiol. 1982 Feb 1;49(2):420–424. [Abstract] [Google Scholar]
  • Teoh KH, Christakis GT, Weisel RD, Madonik MM, Ivanov J, Wong PY, Mee AV, Levitt D, Benak A, Reilly P, et al. Blood conservation with membrane oxygenators and dipyridamole. Ann Thorac Surg. 1987 Jul;44(1):40–47. [Abstract] [Google Scholar]
  • Teoh KH, Christakis GT, Weisel RD, Wong PY, Mee AV, Ivanov J, Madonik MM, Levitt DS, Reilly PA, Rosenfeld JM, et al. Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1988 Aug;96(2):332–341. [Abstract] [Google Scholar]
  • Parry MJ, Randall MJ, Tyler HM, Myhre E, Dale J, Thaulow E. Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leukocytes in angina patients and healthy volunteers. Lancet. 1982 Jul 17;2(8290):164–164. [Abstract] [Google Scholar]
  • Harajola PT, Meurala H, Frick MH. Prevention of early reocclusion by dipyridamole and ASA in arterial reconstructive surgery. J Cardiovasc Surg (Torino) 1981 Mar-Apr;22(2):141–144. [Abstract] [Google Scholar]
  • Bedford RF, Ashford TP. Aspirin pretreatment prevents post-cannulation radial-artery thrombosis. Anesthesiology. 1979 Aug;51(2):176–178. [Abstract] [Google Scholar]
  • Lembo NJ, Black AJ, Roubin GS, Wilentz JR, Mufson LH, Douglas JS, Jr, King SB., 3rd Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990 Feb 15;65(7):422–426. [Abstract] [Google Scholar]
  • Hess H, Müller-Fassbender H, Ingrisch H, Mietaschk A. Verhütung von Wiederverschlüssen nach Rekanalisation obliterierter Arterien mit der Kathetermethode. Dtsch Med Wochenschr. 1978 Dec 15;103(50):1994–1997. [Abstract] [Google Scholar]
  • De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell'Amico F, L'Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb Haemost. 1985 Aug 30;54(2):528–532. [Abstract] [Google Scholar]
  • Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation. 1993 May;87(5):1524–1530. [Abstract] [Google Scholar]
  • Harker LA, Bernstein EF, Dilley RB, Scala TE, Sise MJ, Hye RJ, Otis SM, Roberts RS, Gent M. Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med. 1992 May 1;116(9):731–736. [Abstract] [Google Scholar]
  • Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992 Dec 12;340(8833):1421–1425. [Abstract] [Google Scholar]
  • Fornaro G, Rossi P, Mantica PG, Caccia ME, Aralda D, Lavezzari M, Pamparana F, Milanesi G. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation. 1993 Jan;87(1):162–164. [Abstract] [Google Scholar]
  • Pirk J, Rohn V, Peregrin J. The effect of ibustrin on early aortocoronary bypass patency. Cor Vasa. 1990;32(3):258–262. [Abstract] [Google Scholar]
  • Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation. 1991 Oct;84(4):1568–1580. [Abstract] [Google Scholar]
  • Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation. 1993 May;87(5):1563–1569. [Abstract] [Google Scholar]
  • Baumgartner I, Schalch I, Bollinger A. Doppelblindstudie zur Wirkung von Dipyridamol bei Patienten mit Claudicatio Intermittens. Vasa. 1992;21(4):387–391. [Abstract] [Google Scholar]
  • Pratschner T, Kretschmer G, Prager M, Wenzl E, Polterauer P, Ehringer H, Horvath R, Holzner H. Antiplatelet therapy following carotid bifurcation endarterectomy. Evaluation of a controlled clinical trial. Prognostic significance of histologic plaque examination on behalf of survival. Eur J Vasc Surg. 1990 Jun;4(3):285–289. [Abstract] [Google Scholar]
  • Nevelsteen A, Mortelmans L, Van de Cruys A, Merckx E, Verhaeghe R. Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting. Thromb Res. 1991 Nov 1;64(3):363–369. [Abstract] [Google Scholar]
  • Savage MP, Goldberg S, Macdonald RG, Bass TA, Margolis JR, Whitworth HB, Taussig AS, Vetrovec G, Cowley M, Bove AA, et al. Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. Am Heart J. 1991 Nov;122(5):1239–1244. [Abstract] [Google Scholar]
  • Minar E, Ahmadi R, Koppensteiner R, Stümpflen A, Ehringer H. Randomisierte Vergleichsstudie zur Rezidivrate nach femoropoplitealer PTA: hohe (1.0 g/die) vs. niedrige (0.1 g/die) ASS-Dosis. Vasa Suppl. 1991;33:167–167. [Abstract] [Google Scholar]
  • Lassila R, Lepäntalo M, Lindfors O. The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg. 1991 May-Jun;15(3):378–382. [Abstract] [Google Scholar]
  • Blanchard JF, Carreras LO. A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group. Nouv Rev Fr Hematol. 1992;34(2):149–153. [Abstract] [Google Scholar]
  • Ollivier JP. Etude de la perméabilité des pontages aortocoronaires à 6 mois. Etude multicentrique française. Arch Mal Coeur Vaiss. 1991 Apr;84(4):537–542. [Abstract] [Google Scholar]
  • Ekeström SA, Gunnes S, Brodin UB. Effect of dipyridamole (Persantin) on blood flow and patency of aortocoronary vein bypass grafts. Scand J Thorac Cardiovasc Surg. 1990;24(3):191–196. [Abstract] [Google Scholar]
  • Ranke C, Hecker H, Creutzig A, Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 1993 Jun;87(6):1873–1879. [Abstract] [Google Scholar]
  • van der Meer J, Hillege HL, Kootstra GJ, Ascoop CA, Mulder BJ, Pfisterer M, van Gilst WH, Lie KI. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Lancet. 1993 Jul 31;342(8866):257–264. [Abstract] [Google Scholar]
  • Putz P, Buyse H, Delvaux D, Kutnowski M, Demulder A, Dumont N, Lavenne E, Claes R, Rosillon D. Triflusal versus acetylsalicylic acid: a double-blind study for the prophylaxis of deep vein thrombosis after hip surgery. Acta Chir Belg. 1991 Nov-Dec;91(6):269–276. [Abstract] [Google Scholar]
  • Belcaro G, Errichi BM, De Simone P. Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning. Angiology. 1993 Apr;44(4):328–331. [Abstract] [Google Scholar]
  • Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 1992 Jul 6;68(1):1–6. [Abstract] [Google Scholar]
  • Turpie AG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993 Aug 19;329(8):524–529. [Abstract] [Google Scholar]
  • Joseph R, Welch KM, D'Andrea G. Effect of therapy on platelet activating factor-induced aggregation in acute stroke. Stroke. 1989 May;20(5):609–611. [Abstract] [Google Scholar]
  • Apollonio A, Castignani P, Magrini L, Angeletti R. Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. J Int Med Res. 1989 Jan-Feb;17(1):28–35. [Abstract] [Google Scholar]
  • Sancho Rieger J, López-Trigo Picho J. Efecto de ticlopidina en la prevención de la recidiva de los accidentes isquémicos cerebrales: estudio comparativo con dipiridamol. Med Clin (Barc) 1984 Jan 21;82(2):62–64. [Abstract] [Google Scholar]
  • Matías-Guiu J, Dávalos A, Picó M, Monasterio J, Vilaseca J, Codina A. Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand. 1987 Dec;76(6):413–421. [Abstract] [Google Scholar]
  • Eriksson SE. Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. Acta Neurol Scand. 1985 Jun;71(6):485–493. [Abstract] [Google Scholar]
  • Burén A, Ygge J. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke. 1981 Sep-Oct;12(5):578–580. [Abstract] [Google Scholar]
  • Hynes KM, Gau GT, Rutherford BD, Kazmier FJ, Frye RL. Effect of aspirin on brachial artery occlusion following brachial arteriotomy for coronary arteriography. Circulation. 1973 Mar;47(3):554–557. [Abstract] [Google Scholar]
  • Freed MD, Rosenthal A, Fyler D. Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin. Am Heart J. 1974 Mar;87(3):283–286. [Abstract] [Google Scholar]
  • Hoffman W, Förster W. Two year Cottbus reinfarction study with 30 mg aspirin per day. Prostaglandins Leukot Essent Fatty Acids. 1991 Nov;44(3):159–169. [Abstract] [Google Scholar]
  • Popescu P, Moldovan T, Anghel S, Filip Z, Rusănescu M. Tratamentul profilactic cu aspirină în angorul instabil (notă preliminară). Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1986 Nov-Dec;38(6):525–529. [Abstract] [Google Scholar]
  • Mayer JE, Jr, Lindsay WG, Castaneda W, Nicoloff DM. Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. Ann Thorac Surg. 1981 Mar;31(3):204–210. [Abstract] [Google Scholar]
  • LEIBERMAN A, GUGLIELMELLI S. PERSANTIN-- A DOUBLE BLIND STUDY. Angiology. 1964 Jun;15:290–292. [Abstract] [Google Scholar]
  • KINSELLA D, TROUP W, McGREGOR M. Studies with a new coronary vasodilator drug: persantin. Am Heart J. 1962 Feb;63:146–151. [Abstract] [Google Scholar]
  • Taguchi K, Matsumura H, Washizu T, Harao M, Kato K, Kato E, Mochizuki T, Takamura K, Mashimo I, Mirifuji K, et al. Effect of athrombogenic therapy, especially high dose therapy of dipyridamole, after prosthetic valve replacement. J Cardiovasc Surg (Torino) 1975 Jan-Feb;16(1):8–15. [Abstract] [Google Scholar]
  • Bran M, Capel P, Messin R. Reduction of platelet activity in patients with prosthetic heart valves. Rev Med Brux. 1980 Feb;1(2):71–75. [Abstract] [Google Scholar]
  • Col-de Beys C, Ferrant A, Moriau M. Effects of suloctidil on platelet survival time following cardiac valve replacement. Thromb Haemost. 1981 Aug 28;46(2):550–553. [Abstract] [Google Scholar]
  • Clyne CA, Archer TJ, Atuhaire LK, Chant AD, Webster JH. Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg. 1987 Apr;74(4):246–248. [Abstract] [Google Scholar]
  • Satiani B. A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology. 1985 Sep;36(9):608–616. [Abstract] [Google Scholar]
  • Esmatjes E, Maseras M, Gállego M, Coves MJ, Conget I. Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up. Diabetes Res Clin Pract. 1989 Nov 6;7(4):285–291. [Abstract] [Google Scholar]
  • Browse NL, Hall JH. Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis. Lancet. 1969 Oct 4;2(7623):718–720. [Abstract] [Google Scholar]
  • Buttermann G, Theisinger W, Weidenbach A, Hartung R, Welzel D, Pabst HW. Quantitative Bewertung der postoperativen Thromboembolieprophylaxe. Vergleichende Untersuchungen über Thrombose- und Emboliehäufigkeiten unter Acetylsalicylsäure, Dextran, Dihydroergotamin, Heparin sowie der fixen Kombination von Heparin und Dihydroergotamin. Med Klin. 1977 Oct 7;72(40):1624–1638. [Abstract] [Google Scholar]
  • O'Brien JR, Tulevski V, Etherington M. Two in-vivo studies comparing high and low aspirin dosage. Lancet. 1971 Feb 20;1(7695):399–400. [Abstract] [Google Scholar]
  • Alho A, Stangeland L, Røttingen J, Wiig JN. Prophylaxis of venous thromboembolism by aspirin, warfarin and heparin in patients with hip fracture. A prospective clinical study with cost-benefit analysis. Ann Chir Gynaecol. 1984;73(4):225–228. [Abstract] [Google Scholar]
  • Silvergleid AJ, Bernstein R, Burton DS, Tanner JB, Silverman JF, Schrier SL. ASA-dipyridamole prophylaxis in elective total hip replacement. Orthopedics. 1978 Jan-Feb;1(1):19–25. [Abstract] [Google Scholar]
  • Guyer RD, Booth RE, Jr, Rothman RH. The detection and prevention of pulmonary embolism in total hip replacement. A study comparing aspirin and low-dose warfarin. J Bone Joint Surg Am. 1982 Sep;64(7):1040–1044. [Abstract] [Google Scholar]
  • Salzman EW, Harris WH, DeSanctis RW. Reduction in venous thromboembolism by agents affecting platelet function. N Engl J Med. 1971 Jun 10;284(23):1287–1292. [Abstract] [Google Scholar]
  • Hey D, Heinrich D, Burkhardt H. Zur Prophylaxe thromboembolischer Komplikationen bei grossen Hüftgelenkseingriffen. Eine vergleichende kontrollierte Studie mit subkutanem Kalziumheparinat und Azetylsalizylsäure. Munch Med Wochenschr. 1973 Nov 2;115(44):1967–1970. [Abstract] [Google Scholar]
  • Tscherne H, Westermann K, Trentz O, Pretschner P, Mellmann J. Thromboembolische Komplikationen und ihre Prophylaxe beim Hüftgelenksersatz. Unfallheilkunde. 1978 Mar;81(3):178–187. [Abstract] [Google Scholar]
  • Schöndorf TH, Hey D. Combined administration of low dose heparin and aspirin as prophylaxis of deep vein thrombosis after hip joint surgery. Haemostasis. 1976;5(4):250–257. [Abstract] [Google Scholar]
  • Schöndorf TH, Hey D. Modified "low-dose" heparin prophylaxis to reduce thrombosis after hip joint operations. Thromb Res. 1978 Jan;12(1):153–163. [Abstract] [Google Scholar]
  • Szabó R, Gyetvai A, Kohán M, Varga G, Lengyel A. Colfarit szerepe az idöskori pulmonalis embólia prevenciójában. Orv Hetil. 1988 Sep 18;129(38):2023–2025. [Abstract] [Google Scholar]
  • Heikinheimo R, Järvinen K. Acetylsalicylic acid and arteriosclerotic-thromboembolic diseases in the aged. J Am Geriatr Soc. 1971 May;19(5):403–405. [Abstract] [Google Scholar]
  • Herskovits E, Famulari A, Tamaroff L, Gonzalez AM, Vázquez A, Dominguez R, Fraiman H, Vila J. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol. 1985;24(1):73–81. [Abstract] [Google Scholar]
  • Herskovits E, Vazquez A, Famulari A, Smud R, Tamaroff L, Fraiman H, Gonzalez AM, Vila J, Matera V. Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks. Lancet. 1981 May 2;1(8227):966–968. [Abstract] [Google Scholar]
  • Dehen H, Dordain G, Doyon F. Prévention secondaire des infarctus cérébraux dus à l'athérosclérose. Comparaison à trois ans du flurbiproféne et d'un dérivé de l'ergot de seigle. Presse Med. 1984 Jan 21;13(2):87–90. [Abstract] [Google Scholar]
  • De Martiis M, Parenzi A, Barlattani A, De Martiis A. Studio clinico randomizzato sull'efficacia del buflomedil nella prevenzione delle recidive di ischemia cerebrale in confronto con antiaggreganti piastrinici. Clin Ter. 1986 Mar 15;116(5):367–371. [Abstract] [Google Scholar]
  • Gårde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne LG, Ostman J. Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke. 1983 Sep-Oct;14(5):677–681. [Abstract] [Google Scholar]
  • Biller J, Bruno A, Adams HP, Jr, Godersky JC, Loftus CM, Mitchell VL, Banwart KJ, Jones MP. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. Stroke. 1989 Apr;20(4):441–447. [Abstract] [Google Scholar]
  • Olsson JE, Brechter C, Bäcklund H, Krook H, Müller R, Nitelius E, Olsson O, Tornberg A. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke. 1980 Jan-Feb;11(1):4–9. [Abstract] [Google Scholar]
  • Rothlin ME, Pfluger N, Speiser K, Goebel N, Krayenbühl HP, Steinbrunn W, Turina M, Senning A. Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. Eur Heart J. 1985 Feb;6(2):168–175. [Abstract] [Google Scholar]
  • Thornton MA, Gruentzig AR, Hollman J, King SB, 3rd, Douglas JS. Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation. 1984 Apr;69(4):721–727. [Abstract] [Google Scholar]
  • Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Aust N Z J Med. 1990 Aug;20(4):549–552. [Abstract] [Google Scholar]
  • Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, Chow J, Ng RP, Tse TF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation. 1985 Nov;72(5):1059–1063. [Abstract] [Google Scholar]
  • Cospite M, Ferrara F, Milio G, Scrivano V, Meli F. Ticlopidine in the treatment of multiple atherosclerotic arteriopathy: a strain gauge plethysmography and Döppler spectrum analysis evaluation. J Int Med Res. 1987 Sep-Oct;15(5):303–311. [Abstract] [Google Scholar]
  • Noppeney T, Kasprzak P, Raithel D, Hirche H. Uber den Einsatz von Naftidrofuryl bei Patienten mit femoro-poplitealem Kunststoff-Bypass. Vasa Suppl. 1988;24:60–66. [Abstract] [Google Scholar]
  • Zeitler E, Reichold J, Schoop W, Loew D. Einfluss von Acetylsalicylsäure auf das Frühergebnis nach perkutaner Rekanalisation arterieller Obliterationen nach Dotter. Dtsch Med Wochenschr. 1973 Jun 29;98(26):1285–1288. [Abstract] [Google Scholar]
  • Kajanoja P, Forss M. Prevention of venous thrombosis by dipyridamole-naproxen and low-dose heparin in patients undergoing hysterectomy. Ann Clin Res. 1981 Dec;13(6):392–395. [Abstract] [Google Scholar]
  • Gruber UF, Buser P, Frick J, Loosli J, Matt E, Segesser D. Sulfinpyrazone and postoperative deep vein thrombosis. Eur Surg Res. 1977;9(5):303–310. [Abstract] [Google Scholar]
  • Brommer EJ. The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy. J Int Med Res. 1981;9(3):203–210. [Abstract] [Google Scholar]
  • Pini M, Spadini E, Carluccio L, Giovanardi C, Magnani E, Ugolotti U, Uggeri E. Dextran/aspirin versus heparin/dihydroergotamine in preventing thrombosis after hip fractures. J Bone Joint Surg Br. 1985 Mar;67(2):305–309. [Abstract] [Google Scholar]
  • Orthner E, Hertz H, Kwasny O, Maier R, Zekert F, Schemper M, Höfer R, Bergmann H, Havlick E, Wohlzogen FX, et al. Thromboembolieprophylaxe bei hüftgelenknahen Oberschenkelfrakturen--Ergebnisse einer prospektiven randomisierten Studie zwischen Heparin-DHE und ASS-DHE. Unfallchirurgie. 1990 Jun;16(3):128–138. [Abstract] [Google Scholar]
  • Harris WH, Salzman EW, Athanasoulis C, Waltman AC, Baum S, DeSanctis RW. Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg Am. 1974 Dec;56(8):1552–1562. [Abstract] [Google Scholar]
  • Cavin R. Etude comparative de deux méthodes de prophylaxie des thrombo-embolies dans 108 cas de prothèse totale de hanche. Rev Med Suisse Romande. 1977 Nov;97(11):531–549. [Abstract] [Google Scholar]
  • Josefsson G, Dahlqvist A, Bodfors B. Prevention of thromboembolism in total hip replacement. Aspirin versus dihydroergotamine-heparin. Acta Orthop Scand. 1987 Dec;58(6):626–629. [Abstract] [Google Scholar]
  • Schöndorf TH, Weber U, Lasch HG. Niedrig dosiertes Heparin und Acetylsalicylsäure nach elektiven Operationen am Hüftgelenk. Untersuchungen zur antithrombotischen Wirkung. Dtsch Med Wochenschr. 1977 Sep 16;102(37):1314–1318. [Abstract] [Google Scholar]
  • Stern D, Vasey H. Association de dihydroergotamine et d'acide acétylsalicylique--prophylaxie des complications thromboemboliques postopératoires. Etude clinique en orthopédie. Schweiz Med Wochenschr. 1987 Dec 19;117(51):2084–2088. [Abstract] [Google Scholar]
  • Peters SH, Jonker JJ, de Boer AC, den Ottolander GJ. The incidence of deep venous thrombosis in patients with an acute myocardial infarction treated with acenocoumarol or indobufen. Thromb Haemost. 1982 Oct 29;48(2):222–225. [Abstract] [Google Scholar]
  • Rogers PH, Walsh PN, Marder VJ, Bosak GC, Lachman JW, Ritchie WG, Oppenheimer L, Sherry S. Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. J Bone Joint Surg Am. 1978 Sep;60(6):758–762. [Abstract] [Google Scholar]
  • Hume M, Kuriakose TX, Zuch L, Turner RH. 125I fibrinogen and the prevention of venous thrombosis. Arch Surg. 1973 Nov;107(5):803–806. [Abstract] [Google Scholar]
  • Tillberg B. Prevention of postoperative deep vein thrombosis by leg bandaging and oxyphenbutazone. Br Med J. 1976 May 22;1(6020):1256–1257. [Europe PMC free article] [Abstract] [Google Scholar]
  • FOULDS T, MACKINNON J. Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J. 1960 Sep 17;2(5202):835–835. [Europe PMC free article] [Abstract] [Google Scholar]
  • DEWAR HA, HORLER AR. A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J. 1961 Apr;6:149–152. [Abstract] [Google Scholar]
  • Davis JW, Lewis HD, Jr, Phillips PE, Schwegler RA, Yue KT, Hassanein KR. Effect of aspirin on exercise-induced angina. Clin Pharmacol Ther. 1978 May;23(5):505–510. [Abstract] [Google Scholar]
  • Hendra T, Collins P, Penny W, Sheridan DJ. Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris. Int J Cardiol. 1984 Mar;5(3):382–385. [Abstract] [Google Scholar]
  • Hendra T, Collins P, Penny W, Sheridan D. Dazoxiben in stable angina. Lancet. 1983 May 7;1(8332):1041–1041. [Abstract] [Google Scholar]
  • Fox KM, Jonathan A, Selwyn AP. Effects of platelet inhibition on myocardial ischaemia. Lancet. 1982 Oct 2;2(8301):727–730. [Abstract] [Google Scholar]
  • Khurmi NS, Bowles MJ, Raftery EB. Are anti-platelet drugs of value in the management of patients with chronic stable angina? A study with ticlopidine. Clin Cardiol. 1986 Oct;9(10):493–498. [Abstract] [Google Scholar]
  • Stratton JR, Ritchie JL. Effect of suloctidil on tomographically quantitated platelet accumulation in Dacron aortic grafts. Am J Cardiol. 1986 Jul 1;58(1):152–156. [Abstract] [Google Scholar]
  • Stratton JR, Ritchie JL. Failure of ticlopidine to inhibit deposition of indium-111-labeled platelets on Dacron prosthetic surfaces in humans. Circulation. 1984 Apr;69(4):677–683. [Abstract] [Google Scholar]
  • Kellett John M. Aspirin for strokes and transient ischaemic attacks. BMJ. 1988 Dec 03;297(6661):b1473–1473. [Europe PMC free article] [Google Scholar]
  • Shapiro LM, Cove DH, Trethowan N, Neumann V. Clinical trials of an antiplatelet agent, ticlopidine, in diabetes mellitus. Curr Med Res Opin. 1983;8(7):518–523. [Abstract] [Google Scholar]
  • Evans G. Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ishcemia. Surg Forum. 1972;23(0):239–241. [Abstract] [Google Scholar]
  • Hopper AH, Tindall H, Davies JA. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy. Nephrol Dial Transplant. 1989;4(2):140–143. [Abstract] [Google Scholar]
  • Moriau M, Col-De Beys C, Pardonge E, Ferrant A. Clinical and biological activity of the antiplatelet agent suloctidil in treatment of idiopathic recurrent vein thrombosis (I.R.V.T.). Thromb Haemost. 1982 Feb 26;47(1):27–31. [Abstract] [Google Scholar]
  • Thun MJ, Namboodiri MM, Heath CW., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. [Abstract] [Google Scholar]
  • Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. [Europe PMC free article] [Abstract] [Google Scholar]
  • Hennekens CH, Buring JE, Sandercock PAG, Gray R, Wheatley K, Collins R, Doll R, Peto R. Aspirin use and chronic diseases. BMJ. 1990 Jan 13;300(6717):b117–118. [Europe PMC free article] [Google Scholar]
  • Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993 Mar;35(3):219–226. [Europe PMC free article] [Abstract] [Google Scholar]
  • Sandercock PA, van den Belt AG, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):17–25. [Europe PMC free article] [Abstract] [Google Scholar]
  • Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991 May 15;114(10):835–839. [Abstract] [Google Scholar]
  • Wellens HJ, Brugada P, Stevenson WG. Programmed electrical stimulation of the heart in patients with life-threatening ventricular arrhythmias: what is the significance of induced arrhythmias and what is the correct stimulation protocol? Circulation. 1985 Jul;72(1):1–7. [Abstract] [Google Scholar]
  • Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci. 1989 Nov;10(11):453–458. [Abstract] [Google Scholar]
  • Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991 Oct 17;325(16):1137–1141. [Abstract] [Google Scholar]
  • Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J. 1991 Mar;12(3):428–433. [Abstract] [Google Scholar]
  • Dyken ML, Barnett HJ, Easton JD, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG. Low-dose aspirin and stroke. "It ain't necessarily so". Stroke. 1992 Oct;23(10):1395–1399. [Abstract] [Google Scholar]
Articles from The BMJ are provided here courtesy of BMJ Publishing Group

Full text links 

Free to read at bmj.bmjjournals.com
http://bmj.bmjjournals.com/cgi/content/abstract/308/6921/81

Free to read at bmj.bmjjournals.com
http://bmj.bmjjournals.com/cgi/content/full/308/6921/81

Citations & impact 

Impact metrics

502
Citations
Jump to Citations
1
Data citation
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/1767356
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/1767356

Article citations

Go to all (502) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.